

Supplementary Table 2 : Clinical characteristics of BC patients enrolled in the IHC study

	N (%)		CD163		p value
			0	1-2	
	N	238	109	129	
Age (Years)					0,143
median	57(27,3-87,4)		57 (27,3 87,4)	56.8 (30,4 - 82,7)	
<50	77 (32,4)		30 (27,5)	47 (37,1)	
>50	161 (67,6)		79 (72,5)	82 (62,9)	
Tumor size (mm)					0,145
<30	152 (63,9)		75 (68,8)	77 (59,7)	
≥ 30	86 (36,1)		34 (31,2)	52 (40,3)	
Menopause					0,071
Unknown	3		3	0	
No	81 (34,5)		30 (28,3)	51 (40,5)	
Yes	154 (65,5)		76 (71,7)	78 (59,5)	
SBR grade					<0,001
1	38 (16)		30 (27,5)	8 (6,9)	
2	99 (41,6)		53 (46,8)	46 (37,9)	
3	101 (42,4)		26 (23,9)	75 (55,2)	
Lymph node involvement					0,003
unknown	1		0	1	
no	87 (36,7)		51 (46,8)	36 (27)	
yes	150 (63,3)		58 (53,2)	92 (73)	
Lymphatic emboles					0,002
No	118 (49,6)		66 (60,6)	52 (40,3)	
Yes	120 (50,4)		43 (39,4)	77 (59,7)	
Molecular subtypes					<0,001
Unknown	11		6	5	
Luminal A	116 (51,1)		74 (71,8)	42 (36,9)	
Luminal B	85 (7,4)		24 (23,3)	61 (50,5)	
Her2/neu amplified	6 (2,6)		2 (1,9)	4 (2,7)	
Triple Negative	20 (8,8)		3 (2,9)	17 (9,9)	